Phase 1 Epilepsy Trial, Recruiting NCT06016686 Sponsor: University of Minnesota Condition: Epilepsy
Back to Epilepsy

Phase 1 Epilepsy Trial, Recruiting

NCT06016686
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are between 18 and 40 years of age
  • People who speak English
  • People who have Medicare or equivalent health insurance from a partner country

Who may not be able to join:

  • People who are currently pregnant
  • People who smoke and are not willing to avoid smoking on the day of the experiment
  • People who are unable or unwilling to sign a written consent form
  • People who have difficulty standing on their own for 5 minutes during a tilt-table test (a test where a person lies on a table that is slowly tilted upright)
  • People found to have a significant buildup in the walls of the main arteries in the neck, detected during an ultrasound scan as part of the study visit
  • People whose vagus nerve (a major nerve in the neck) cannot be seen clearly on an ultrasound scan
  • People whose existing nerve stimulation electrodes are not in a suitable position for the study procedure
  • People excluded for any other medical reason as determined by the research team (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Vaughan G Macefield, PhD, Monash University

Phone: 612-625-5018

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Registry
ClinicalTrials.gov
Start date
1 April 2024
Est. completion
31 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

identify action potential morphology of specific fibers activated by vagal nerve stimulation (VNS); identify ratio of myelinated fibers in specific fibers activated by vagal nerve stimulation (VNS); physiological identification of the specific fibers activated by vagal nerve stimulation (VNS); identify firing rates of the specific fibers activated by vagal nerve stimulation (VNS); identify stimulus current required to activate specific fibers activated by vagal nerve stimulation (VNS); differences in firing rates of cardiac parasympathetic vagal activity; Discharge variability of cardiac paras...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov